nach oben

Journal of Thrombosis and Thrombolysis

Erschienen in:

27.03.2020

Ticagrelor for the primary prevention of stroke in patients with coronary artery disease: a systematic review and meta-analysis of randomized controlled trials

verfasst von: Qi Kong, Xin Ma, Xiaoxi Zhao, Fei Chen, Chengbei Hou

Erschienen in: Journal of Thrombosis and Thrombolysis | Ausgabe 4/2020

Einloggen, um Zugang zu erhalten

Abstract

Coronary artery disease (CAD) patients had a higher risk of first-ever stroke than general population even when they were on antiplatelet treatment. It was unknown whether more potent antiplatelet inhibitor ticagrelor which also provided adenosine-mediated protection would improve the primary stroke prevention for CAD. PubMed, Embase, Web of Science and CERNTRAL were searched for randomized clinical trials (RCTs) comparing efficacy and safety outcomes of over 30-day use of ticagrelor versus other antiplatelet drugs or placebo in patients with acute or chronic coronary syndrome. RCTs involving patients with any stroke history were excluded. Based on 5 RCTs with 45,843 patients, ticagrelor-involving regimens significantly reduced first-ever strokes (risk ratio [RR] 0.81; 95% confidential interval [CI] 0.71–0.94; I² = 0%) in comparison to other antiplatelet regimens in CAD, where the benefits in reducing ischemic strokes (IS) (RR 0.80; 95% CI 0.68–0.94; I² = 0%) was not canceled out by the increase of intracranial hemorrhage (ICH) (RR 1.41; 95% CI 1.05–1.89; I² = 0%). According to results of subgroup analyses, the protective effects of ticagrelor on first-ever stroke were more significant with treatment duration of more than 1 year, dosage of 60 mg twice daily, and in clinical settings of chronic coronary syndrome. In conclusion, available evidence from aggregate data supported a modest advantage of ticagrelor-involving regimens for the primary stroke prevention in CAD compared with other antiplatelet regimens after the trade-off between reducing IS and inducing ICH, where more benefits might be expected from long-term and low-dose use of ticagrelor among patients with chronic coronary syndrome. Further collaborative meta-analysis of individual participant data from well-designed and statistically-powered trials would be needed to generate high quality evidence on this issue.

Nur mit Berechtigung zugänglich

Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Das SR, Delling FN, Djousse L, Elkind M, Ferguson JF, Fornage M, Jordan LC, Khan SS, Kissela BM, Knutson KL, Kwan TW, Lackland DT, Lewis TT, Lichtman JH, Longenecker CT, Loop MS, Lutsey PL, Martin SS, Matsushita K, Moran AE, Mussolino ME, O'Flaherty M, Pandey A, Perak AM, Rosamond WD, Roth GA, Sampson U, Satou GM, Schroeder EB, Shah SH, Spartano NL, Stokes A, Tirschwell DL, Tsao CW, Turakhia MP, VanWagner LB, Wilkins JT, Wong SS, Virani SS (2019) Heart disease and stroke statistics-2019 update: a report from the American Heart Association. Circulation 139:e56–e528. https://doi.org/10.1161/CIR.0000000000000659CrossRefPubMed

Kannel WB, Wolf PA, Verter J (1983) Manifestations of coronary disease predisposing to stroke. The Framingham study. JAMA 250:2942–2946CrossRef

Sacco RL, Wolf PA, Kannel WB, McNamara PM (1982) Survival and recurrence following stroke. The Framingham study. Stroke 13:290–295. https://doi.org/10.1161/01.str.13.3.290CrossRefPubMed

Amarenco P, Lavallee PC, Labreuche J, Ducrocq G, Juliard JM, Feldman L, Cabrejo L, Meseguer E, Guidoux C, Adrai V, Ratani S, Kusmierek J, Lapergue B, Klein IF, Gongora-Rivera F, Jaramillo A, Abboud H, Olivot JM, Mazighi M, Touboul PJ, Steg PG (2013) Coronary artery disease and risk of major vascular events after cerebral infarction. Stroke 44:1505–1511. https://doi.org/10.1161/STROKEAHA.111.000142CrossRefPubMed

Bonaca MP, Goto S, Bhatt DL, Steg PG, Storey RF, Cohen M, Goodrich E, Mauri L, Ophuis TO, Ruda M, Spinar J, Seung KB, Hu D, Dalby AJ, Jensen E, Held P, Morrow DA, Braunwald E, Sabatine MS (2016) Prevention of stroke with ticagrelor in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54 (prevention of cardiovascular events in patients with prior heart attack using ticagrelor compared to placebo on a background of aspirin-thrombolysis in myocardial infarction 54). Circulation 134:861–871. https://doi.org/10.1161/CIRCULATIONAHA.116.024637CrossRefPubMed

Gallo A, Galliazzo S, Grazioli S, Guasti L, Ageno W, Squizzato A (2019) Epidemiology and secondary prevention of ischemic stroke in patients on antiplatelet drug: a retrospective cohort study. J Thromb Thrombolysis 48:336–344. https://doi.org/10.1007/s11239-019-01893-yCrossRefPubMed

Hiatt WR, Fowkes FG, Heizer G, Berger JS, Baumgartner I, Held P, Katona BG, Mahaffey KW, Norgren L, Jones WS, Blomster J, Millegard M, Reist C, Patel MR (2017) Ticagrelor versus clopidogrel in symptomatic peripheral artery disease. N Engl J Med 376:32–40. https://doi.org/10.1056/NEJMoa1611688CrossRefPubMed

Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, Freij A, Thorsen M (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361:1045–1057. https://doi.org/10.1056/NEJMoa0904327CrossRefPubMed

Albers GW, Amarenco P (2001) Combination therapy with clopidogrel and aspirin: can the CURE results be extrapolated to cerebrovascula patients? Stroke 32:2948–2949. https://doi.org/10.1161/hs1201.100829CrossRefPubMed

10.

Held P, Himmelmann A, Ditmarsch M (2016) Ticagrelor for the treatment of atherosclerotic disease: insights from the PARTHENON clinical development program. Future Cardiol 12:405–418. https://doi.org/10.2217/fca-2016-0028CrossRefPubMed

11.

Verdoia M, Kedhi E, Suryapranata H, De Luca G (2019) Ticagrelor in the prevention of coronary and non-coronary atherothrombotic events: a comprehensive meta-analysis of 10 randomized trials. Atherosclerosis 284:136–147. https://doi.org/10.1016/j.atherosclerosis.2019.02.011CrossRefPubMed

12.

Malhotra K, Goyal N, Kasunich AS, Sheth SA, Katsanos AH, Alexandrov AV, Tsivgoulis G (2018) Ticagrelor for stroke prevention in patients with vascular risk factors: a systematic review and meta-analysis. J Neurol Sci 390:212–218. https://doi.org/10.1016/j.jns.2018.05.001CrossRefPubMed

13.

Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, Prescott E, Storey RF, Deaton C, Cuisset T, Agewall S, Dickstein K, Edvardsen T, Escaned J, Gersh BJ, Svitil P, Gilard M, Hasdai D, Hatala R, Mahfoud F, Masip J, Muneretto C, Valgimigli M, Achenbach S, Bax JJ (2019) 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. https://doi.org/10.1093/eurheartj/ehz425CrossRefPubMed

14.

Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (eds) (2019) Cochrane handbook for systematic reviews of interventions version 6.0 (updated July 2019). Cochrane. Available from www.training.cochrane.org/handbook

15.

Steg PG, Bhatt DL, Simon T, Fox K, Mehta SR, Harrington RA, Held C, Andersson M, Himmelmann A, Ridderstrale W, Leonsson-Zachrisson M, Liu Y, Opolski G, Zateyshchikov D, Ge J, Nicolau JC, Corbalan R, Cornel JH, Widimsky P, Leiter LA (2019) Ticagrelor in patients with stable coronary disease and diabetes. N Engl J Med 381:1309–1320. https://doi.org/10.1056/NEJMoa1908077CrossRefPubMed

16.

Schüpke S, Neumann FJ, Menichelli M, Mayer K, Bernlochner I, Wöhrle J, Richardt G, Liebetrau C, Witzenbichler B, Antoniucci D, Akin I, Bott-Flügel L, Fischer M, Landmesser U, Katus HA, Sibbing D, Seyfarth M, Janisch M, Boncompagni D, Hilz R, Rottbauer W, Okrojek R, Möllmann H, Hochholzer W, Migliorini A, Cassese S, Mollo P, Xhepa E, Kufner S, Strehle A, Leggewie S, Allali A, Ndrepepa G, Schühlen H, Angiolillo DJ, Hamm CW, Hapfelmeier A, Tölg R, Trenk D, Schunkert H, Laugwitz KL, Kastrati A (2019) Ticagrelor or prasugrel in patients with acute coronary syndromes. N Engl J Med 381:1524–1534. https://doi.org/10.1056/NEJMoa1908973CrossRefPubMed

17.

Motovska Z, Hlinomaz O, Kala P, Hromadka M, Knot J, Varvarovsky I, Dusek J, Jarkovsky J, Miklik R, Rokyta R, Tousek F, Kramarikova P, Svoboda M, Majtan B, Simek S, Branny M, Mrozek J, Cervinka P, Ostransky J, Widimsky P (2018) 1-year outcomes of patients undergoing primary angioplasty for myocardial infarction treated with prasugrel versus ticagrelor. J Am Coll Cardiol 71:371–381. https://doi.org/10.1016/j.jacc.2017.11.008CrossRefPubMed

18.

Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, Magnani G, Bansilal S, Fish MP, Im K, Bengtsson O, Oude OT, Budaj A, Theroux P, Ruda M, Hamm C, Goto S, Spinar J, Nicolau JC, Kiss RG, Murphy SA, Wiviott SD, Held P, Braunwald E, Sabatine MS (2015) Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 372:1791–1800. https://doi.org/10.1056/NEJMoa1500857CrossRefPubMed

19.

Bonello L, Laine M, Cluzel M, Frere C, Mancini J, Hasan A, Thuny F, Gaubert M, Guieu R, Dignat-George F, Michelet P, Paganelli F, Kerbaul F (2015) Comparison of ticagrelor versus prasugrel to prevent periprocedural myonecrosis in acute coronary syndromes. Am J Cardiol 116:339–343. https://doi.org/10.1016/j.amjcard.2015.04.050CrossRefPubMed

20.

Bonaca MP, Storey RF, Theroux P, Steg PG, Bhatt DL, Cohen MC, Im K, Murphy SA, Magnani G, Ophuis TO, Rudah M, Parkhomenko A, Isaza D, Kamensky G, Goudev A, Montalescot G, Jensen EC, Johanson P, Braunwald E, Sabatine MS (2017) Efficacy and safety of ticagrelor over time in patients with prior MI in PEGASUS-TIMI 54. J Am Coll Cardiol 70:1368–1375. https://doi.org/10.1016/j.jacc.2017.07.768CrossRefPubMed

21.

Storey RF, Angiolillo DJ, Bonaca MP, Thomas MR, Judge HM, Rollini F, Franchi F, Ahsan AJ, Bhatt DL, Kuder JF, Steg PG, Cohen M, Muthusamy R, Braunwald E, Sabatine MS (2016) Platelet inhibition with ticagrelor 60 mg versus 90 mg twice daily in the PEGASUS-TIMI 54 trial. J Am Coll Cardiol 67:1145–1154. https://doi.org/10.1016/j.jacc.2015.12.062CrossRefPubMed

22.

Roshammar D, Nyberg J, Andersson T, Stanski D, Storey RF, Hamren B (2017) Exposure-response analyses supporting ticagrelor dosing recommendation in patients with prior myocardial infarction. J Clin Pharmacol 57:573–583. https://doi.org/10.1002/jcph.839CrossRefPubMed

23.

Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, Juni P, Kastrati A, Kolh P, Mauri L, Montalescot G, Neumann FJ, Petricevic M, Roffi M, Steg PG, Windecker S, Zamorano JL, Levine GN (2018) 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 39:213–260. https://doi.org/10.1093/eurheartj/ehx419CrossRefPubMed

24.

Bittl JA, Baber U, Bradley SM, Wijeysundera DN (2016) Duration of dual antiplatelet therapy: a systematic review for the 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the american college of cardiology/american heart association task force on clinical practice guidelines. Circulation 134:e156–e178. https://doi.org/10.1161/CIR.0000000000000405CrossRefPubMed

25.

Udell JA, Bonaca MP, Collet JP, Lincoff AM, Kereiakes DJ, Costa F, Lee CW, Mauri L, Valgimigli M, Park SJ, Montalescot G, Sabatine MS, Braunwald E, Bhatt DL (2016) Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials. Eur Heart J 37:390–399. https://doi.org/10.1093/eurheartj/ehv443CrossRefPubMed

26.

James SK, Storey RF, Khurmi NS, Husted S, Keltai M, Mahaffey KW, Maya J, Morais J, Lopes RD, Nicolau JC, Pais P, Raev D, Lopez-Sendon JL, Stevens SR, Becker RC (2012) Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack. Circulation 125:2914–2921. https://doi.org/10.1161/CIRCULATIONAHA.111.082727CrossRefPubMed

Titel: Ticagrelor for the primary prevention of stroke in patients with coronary artery disease: a systematic review and meta-analysis of randomized controlled trials
verfasst von: Qi Kong
Xin Ma
Xiaoxi Zhao
Fei Chen
Chengbei Hou
Publikationsdatum: 27.03.2020
Verlag: Springer US
Erschienen in: Journal of Thrombosis and Thrombolysis / Ausgabe 4/2020
Print ISSN: 0929-5305
Elektronische ISSN: 1573-742X
DOI: https://doi.org/10.1007/s11239-020-02085-9

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Ticagrelor for the primary prevention of stroke in patients with coronary artery disease: a systematic review and meta-analysis of randomized controlled trials

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2020

The Impact of platelet–fibrin clot strength on occurrence and clinical outcomes of peripheral artery disease in patients with significant coronary artery disease

Hyperkoagulabilität auch nach subklinscher COVID-19-Erkrankung?

Thromboseprophylaxe: Richtige Strategie bei der Behandlung von COVID-19 gesucht

Experience of a 40-day (6 week) LMWH treatment for isolated distal deep vein thrombosis

Venous thromboembolism in critically ill COVID-19 patients receiving prophylactic or therapeutic anticoagulation: a systematic review and meta-analysis

Predictors for layered coronary plaques: an optical coherence tomography study

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin